(4S,5R)-5-Ethyl-4-methyl-oxazolidin-2-one | 114744-98-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (4S,5R)-5-Ethyl-4-methyl-oxazolidin-2-one
• 英文别名: (4S,5R)-5-ethyl-4-methyl-1,3-oxazolidin-2-one
• CAS: 114744-98-8
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: FXHSOGQCVNXPBS-CRCLSJGQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  benzyl N-[(2S,3R)-3-hydroxypentan-2-yl]carbamate 在 氢氧化钾 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 以80%的产率得到(4S,5R)-5-Ethyl-4-methyl-oxazolidin-2-one
  参考文献：
  名称：

  A new facile diastereoconversion of 2-amino alcohols involving a novel cyclocarbamation

  摘要：

  DOI：

  10.1016/s0040-4039(01)91366-8

文献信息

• Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists
  申请人：Chackalamannil Samuel

  公开号：US20080090830A1

  公开（公告）日：2008-04-17

  Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bonds the dotted line is optionally a bond or no bonds resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R 3 , R 10 , R 11 , R 32 and R 33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

  具有以下结构的杂环取代的三环化合物，或者该化合物的药用盐或溶剂化合物、异构体或消旋混合物，其中表示一个可选的双键，虚线可以是一个键或无键，从而形成一个双键或一个单键，符合化合价要求，E、A、G、M、Het、B、X、R3、R10、R11、R32和R33在此有定义，其余取代基如规范中所定义，以及含有它们的药物组合物和通过给予该化合物治疗与血栓形成、动脉粥样硬化、再狭窄、高血压、心绞痛、心律失常、心力衰竭和癌症相关的疾病的方法。还声称与其他心血管药物的联合疗法。
• PYRAZOLYL DERIVATIVES AS SYK INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150191461A1

  公开（公告）日：2015-07-09

  The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

  本发明提供了公式I的新型吡唑衍生物，它们是脾酪氨酸激酶的有效抑制剂，并可用于治疗和预防由该酶介导的疾病，如哮喘、慢性阻塞性肺疾病、类风湿性关节炎和癌症。
• KANO, SHINZO;YOKOMATSU, TSUTOMU;IWASAWA, HARUO;SHIBUYA, SHIROSHI, TETRAHEDRON LETT., 28,(1987) N 50, 6331-6334
  作者：KANO, SHINZO、YOKOMATSU, TSUTOMU、IWASAWA, HARUO、SHIBUYA, SHIROSHI

  DOI：——

  日期：——
• BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS
  申请人：Chackalamannil Samuel

  公开号：US20120157403A1

  公开（公告）日：2012-06-21

  Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R 3 , R 10 , R 11 , R 32 and R 33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
• US8153664B2
  申请人：——

  公开号：US8153664B2

  公开（公告）日：2012-04-10